EUVIMEDEUVIMED entdecken
Open Access

PET/CT with Myocardial Blood Flow Assessment Is Prognostic of Cardiac Allograft Vasculopathy Progression and Clinical Outcomes

Nikil Prasad, Erin Harris, Ersilia M DeFilippis, Gabriel Sayer, Margarita Chernovolenko, Paolo C Colombo, Justin Fried, David Bae, Kyung Taek Oh, Jayant Raikhelkar, Sambhavi Sneha Kumar, Melana Yuzefpolskaya und 8 weitere

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.124.268713 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Nikil Prasad und 19 weiteren Autor:innen. Beteiligte Einrichtung: Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York. Hauptthemen laut MEDLINE: Heart Transplantation, Positron Emission Tomography Computed Tomography, Coronary Circulation, Coronary Artery Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac allograft vasculopathy (CAV) causes impaired blood flow in both epicardial vessels and microvasculature and remains a leading cause of posttransplant morbidity and mortality. This study examined the prognostic value and outcomes of CAV, assessed by 13N-ammonia PET/CT myocardial perfusion imaging in heart transplant recipients.

Methods

PET/CT and invasive coronary angiography (ICA) were graded using validated scales. CAV progression was assessed using intrapatient sequences: baseline ICA, interval PET/CT with myocardial blood flow reserve, and subsequent ICA. Intervals between ICAs of 600, 900, and 1200 d were included, and for each, the negative predictive value (NPV) of CAV development was assessed.

Results

In total, 344 heart transplant recipients underwent PET/CT for CAV assessment with a median follow-up of 4.8 y. PET CAV grade 0/1 had an NPV of 0.93, 0.95, and 0.95 at each respective time point for developing an International Society for Heart and Lung Transplantation CAV 2/3 on subsequent ICA. Compared with PET CAV 0, PET CAV 2/3 was associated with a 2.9-fold increased risk of all-cause mortality (hazard ratio, 2.86; 95% CI, 1.36-6.00; P = 0.006). PET CAV 1 had a numerically increased risk (hazard ratio, 2.03; 95% CI, 0.99-4.15; P = 0.054). In a sensitivity analysis of 135 patients with stable International Society for Heart and Lung Transplantation CAV over successive ICA, PET CAV 2/3 remained associated with increased risk of death or retransplantation (hazard ratio, 3.20; 95% CI, 1.18-8.69; P = 0.03).

Conclusion

Noninvasive CAV assessment by PET/CT and myocardial blood flow reserve provides prognostic information and robust NPVs for development of moderate to severe CAV over intervals up to 4 y. These data suggest that, for certain patients, intervals between invasive screenings may be extended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart TransplantationPositron Emission Tomography Computed TomographyCoronary CirculationCoronary Artery DiseaseHumansMaleFemaleMiddle AgedPrognosisDisease ProgressionAdultAllograftsMyocardial Perfusion ImagingTreatment OutcomeAged

Stichwörter der Autor:innen

PET/CTcardiac allograft vasculopathyheart transplantpredictionprognosis

Autor:innen und Institutionen

  • Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York.
  • Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York; and.
  • Department of Radiology, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York.
  • Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York; kjc2142@cumc.columbia.edu.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Prasad, N., Harris, E., DeFilippis, E. M., Sayer, G., Chernovolenko, M., Colombo, P. C., Fried, J., Bae, D., Oh, K. T., Raikhelkar, J., Kumar, S. S., Yuzefpolskaya, M., Topkara, V. K., Castillo, M., Lam, E. Y., Latif, F., Takeda, K., Uriel, N., Einstein, A. J., & Clerkin, K. J. (2025). PET/CT with Myocardial Blood Flow Assessment Is Prognostic of Cardiac Allograft Vasculopathy Progression and Clinical Outcomes. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268713

Vancouver

Prasad N, Harris E, DeFilippis EM, Sayer G, Chernovolenko M, Colombo PC, et al. PET/CT with Myocardial Blood Flow Assessment Is Prognostic of Cardiac Allograft Vasculopathy Progression and Clinical Outcomes. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268713

BibTeX
@article{Prasad2025,
  author = {Prasad, Nikil and Harris, Erin and DeFilippis, Ersilia M and Sayer, Gabriel and Chernovolenko, Margarita and Colombo, Paolo C and Fried, Justin and Bae, David and Oh, Kyung Taek and Raikhelkar, Jayant and Kumar, Sambhavi Sneha and Yuzefpolskaya, Melana and Topkara, Veli K and Castillo, Michelle and Lam, Elaine Y and Latif, Farhana and Takeda, Koji and Uriel, Nir and Einstein, Andrew J and Clerkin, Kevin J},
  title = {PET/CT with Myocardial Blood Flow Assessment Is Prognostic of Cardiac Allograft Vasculopathy Progression and Clinical Outcomes},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.124.268713}
}
Kostenlos starten →